Amphastar (AMPH) Pharmaceuticals announced yesterday morning that the Food and Drug Administration approved the company’s abbreviated new drug application for iron sucrose injection in single ...

The Food and Drug Administration has approved the first generic version of Venofer (iron sucrose) Injection.

According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer ®for the treatment of iron deficiency anemia in patients with ...

Iron injections are safe and well tolerated. Some older forms of iron injection (called “iron dextran”) came with an increased risk for allergic reactions.

These adverse reactions have occurred up to 30 minutes after the administration of iron sucrose injection. Reactions have occurred following the first dose or subsequent doses of iron sucrose.

Monoferric will be supplied in 100mg/mL, 500mg/5mL, and 1000mg/10mL single-dose vials for intravenous infusion after dilution.

The FDA has approved the first-ever IV iron replacement therapy to improve exercise capacity in adults with heart failure. The IV ferric carboxymaltose injection (Injectafer; Daiichi Sankyo Inc ...

Monoferric will be supplied in 100mg/mL, 500mg/5mL, and 1000mg/10mL single-dose vials for intravenous infusion after dilution.